-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
September 2022
-
IASLC CEO Reflects on WCLC 2022
In a Q&A with ILCN, Dr. Karen Kelly looks back at the moments that made lasting impressions and the presentations with the power to change the practice of thoracic oncology.
-
Unclear Informed Consent Forms May Be a Barrier to Trial Participation
Research presented during WCLC 2022 shows patient-centered summaries may help potential participants to better understand the benefits and risks of clinical trials.
-
Get Up to Date on SCLC Brain Metastases, Neuroendocrine Tumors
Experts evaluate available evidence comparing various strategies, including prophylactic cranial irradiation vs. surveillance, stereotactic radiosurgery vs. whole-brain radiotherapy, and more.
-
Data Supports Smoking Cessation as Part Active Lung Cancer Treatment
Experts reviewed data that show smoking can reduce innate immunity and suppress the efficacy of anti-cancer agents, leading to poorer outcomes for patients who continue to smoke after their cancer diagnosis.